Summary

Generic Drugs Market Research Report Information by Type (Simple Generics and Super Generics), by Brand (Pure Generic and Branded Generic), by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, and Others), by Route of Administration (Oral, Topical, Parenteral, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Europe, Asia-Pacific, and Rest of the World - Forecast till 2032

Market Overview
In 2023, the generic drug market was estimated to be worth USD 410.60 billion. During the forecast period (2024-2032), the Generic Drugs Market industry is anticipated to experience a compound annual growth rate (CAGR) of 7.85%, increasing from USD 437.90 billion in 2024 to USD 874.36 billion by 2032. The growth of the global generic drug market is primarily driven by the increasing prevalence of chronic diseases worldwide and the increasing strategic initiatives of market participants. Nevertheless, it is anticipated that the global market's expansion will be impeded by voluntary product recalls from market participants. However, it is anticipated that the market will generate profitable opportunities because of investment in research and development (R&D) for generic medications.
The global generic drug market is experiencing substantial growth because of the increasing prevalence of chronic diseases on a global scale. There is a greater demand for cost-effective treatment options due to the increasing prevalence of conditions such as cancer, neurology, cardiovascular diseases, and inflammatory diseases. Consequently, patients and healthcare providers are increasingly turning to generic medications.

Market segment insights
Simple generics and super generics comprise the Generic Drugs Market segmentation, which is determined by type.
Pure generic and branded generic comprise the Generic Drugs Market segmentation, which is determined by brand.
Central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and other indications comprise the Generic Drugs Market segmentation.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American Generic Drugs market is undergoing substantial growth, which is being driven by the increasing demand for Generic Drugs in hospitals and medical settings, as well as the increasing prevalence of chronic diseases and technological advancements.
The European Generic Drugs market, which is driven by the well-established healthcare infrastructure, collaborations and partnerships between industry actors, research organizations, and healthcare providers, accounted for the second-largest market share. In addition, the Germany Generic Drugs provider is said to possess the highest market share, while the France Generic Drugs provider is expected to be the fastest-growing market in the Europe region.
The Asia-Pacific Generic Drugs market is anticipated to experience the most rapid growth from 2023 to 2032 because of the escalating healthcare expenditure and investments in research and development activities, as well as the emergence of chronic medical disorders, including cancer, diabetes, and cardiovascular diseases. Additionally, China Generic Drugs accounted for the greatest market share, while India Generic Drugs is anticipated to be the fastest-growing market in the Asia-Pacific region.

Major Players
Sun Pharmaceutical Industries Ltd. (India), Lupin Pharmaceuticals, Inc. (India), Endo International plc (Ireland), Aurobindo Pharma (India), Aspen Holdings (South Africa), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Cipla ltd. (India), Fresenius SE & Co. KGaA (Germany), and Novartis AG (Switzerland) are among the key companies in the Generic Drugs market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE
4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS
4.3 RESTRAINTS
4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS
4.4 OPPORTUNITY
4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET
5.3 TRENDS IN DEVELOPMENTS OF INDIVIDUAL MARKETS (EU, USA, INDIA, CHINA, OTHER)
5.4 TRENDS IN THE DEVELOPMENT OF THERAPEUTIC AREAS
5.5 TRENDS IN MANUFACTURING SITES
5.6 TRENDS IN NEW TECHNOLOGICAL PLATFORMS FOR DRUGS
5.7 TRENDS IN IP
5.8 TRENDS IN QUALITY REQUIREMENTS
5.9 TRENDS IN REGULATORY REQUIREMENTS
6 GLOBAL GENERIC DRUGS MARKET, BY TYPE
6.1 OVERVIEW
6.2 SIMPLE GENERICS
6.3 SUPER GENERICS
7 GLOBAL GENERIC DRUGS MARKET, BY BRAND
7.1 OVERVIEW
7.2 PURE GENERIC
7.3 BRANDED GENERIC
8 GLOBAL GENERIC DRUGS MARKET, BY INDICATION
8.1 OVERVIEW
8.2 CENTRAL NERVOUS SYSTEM (CNS)
8.3 CARDIOVASCULAR
8.4 UROLOGY
8.5 ONCOLOGY
8.6 RESPIRATORY
8.7 OTHERS
9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 TOPICAL
9.4 PARENTERAL
9.5 OTHERS
10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY
11 GLOBAL GENERIC DRUGS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 INDIA
11.4.3 JAPAN
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST & AFRICA
11.5.2 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 MARKET SHARE ANALYSIS, 2022
12.3 COMPETITOR DASHBOARD
12.4 PUBLIC PLAYERS STOCK SUMMARY
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
12.6.2 EXPANSION
13 COMPANY PROFILES
13.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 LUPIN PHARMACEUTICALS, INC.
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 ENDO INTERNATIONAL PLC
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 KEY STRATEGIES
13.4 AUROBINDO PHARMA
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 KEY STRATEGIES
13.5 ASPEN HOLDINGS
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCTS OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 KEY STRATEGIES
13.6 CIPLA LTD
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 NOVARTIS AG
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 FRESENIUS SE & CO. KGAA
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 KEY STRATEGIES
13.10 VIATRIS INC.
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 KEY STRATEGIES